Small-molecule cancer drug revenues will reach $32.7 billion in 2016, says Visiongain
The small-molecule targeted cancer therapy revenues will reach a value of $32.7 billion worldwide in 2016, compared with $21.7 billion in 2011, according to Small-Molecule Targeted Cancer Therapies: World Market 2013-2023, published by business information provider Visiongain. The work analyses the USA, Japan, Germany, France, the UK, Spain, Italy (EU5), India and China.
Visiongain forecasts that the overall market for small-molecule targeted cancer therapies will grow steadily to 2023. Rising disease prevalence, along with advances in pharmacotherapy and diagnostics, will stimulate that drug market. The R&D pipeline holds great promise. Also, in most countries, high demand exists for newer, better cancer treatments. There remain many commercial opportunities for small-molecule cancer treatments from 2013 to 2023, the study concludes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze